Consciousness — the internal dialogue that seems to govern one’s thoughts and actions — is far less powerful than people believe, serving as a passive conduit rather than an active force that exerts control, according to a new theory proposed by an SF State researcher.
Associate Professor of Psychology Ezequiel Morsella.
Haptics is a growing field that aims to allow our bodies to control and ultimately ‘feel’ our virtual identity. Instead of using the theorized mechanism of a neural computer link, haptic tech attaches sensors and stimuli to our body. A report by research firm Markets and Markets thinks haptic technology, which could soon include something like a glove that let’s you move a hand in cyberspace, will be worth 30 billion by 2020.
Haptic technology, also known as kinesthetic communication, sounds like something out of science fiction. But products, like the vibrating cell phone, have been out for decades. And there’s more advanced systems on the way. That’s partly because of another hyped field: virtual reality. With pioneering virtual reality headsets like the Oculus Rift poised for release next year, the question becomes: How to make this experience even more immersive.
Continue reading “Haptics Technology: Soon, We Might Be Able To ‘Feel’ Cyberspace” »
A representation of a stable sequential working memory; different information items or memory patterns are shown in different colors. (credit: Image adopted from Rabinovich, M.I. et al. (2014))
Try to remember a phone number. You’re now using “sequential memory,” in which your mind processes a sequence of numbers, events, or ideas. It underlies how people think, perceive, and interact as social beings. To understand how sequential memory works, researchers have built mathematical models that mimic this process.
Cognitive modes
Continue reading “Is your thinking chaotic? There’s a model for that.” »
Treating the brain isn’t like the rest of the body. Your blood-brain barrier shields it; filtering the blood to ensure nothing untoward makes it through. This protection is normally a good thing, but it becomes a problem if you want to deliver therapeutic drugs through it. This method could be a solution.
Smuggling therapeutics
Many diseases like Parkinson’s and Alzheimer’s disease are extremely difficult to treat. Only very specific molecules can make it through the brain’s secure barrier, and most drugs don’t make the cut. This poses a challenge when you want to treat disease inside the brain, and so efforts have been focused on finding a way to overcome this. New research has now demonstrated a way of treating Parkinson’s disease with a surgical treatment that opens up a small route to bypass the barrier; essentially a smuggling hatch into your brain.
But it may offer advantages over these systems, which are often confused by changes to an environment. And researchers hope that the work will not only allow a more efficient way for robots to navigate but also provide neuroscientists a better understanding of place cells, grid cells and cognitive maps.
Remember that paralyzed guy from Southern California who managed to walk on his own accord thanks to a revolutionary technique that bridged the gap in his severed spinal column with a wireless Bluetooth link? A team of doctors at Ohio’s Case Western Reserve University have reportedly accomplished the same feat with a patient’s arms.
The team described its initial findings at a meeting of the Society for Neuroscience in Chicago on Tuesday. The system works much like that of the earlier team at UC Irvine: a brain-control interface (BCI) reads the patient’s brain waves emanating from his motor cortex, converts them into actionable electrical signals and wirelessly transmits them to an actuator “sewn into” the patient’s arm. This actuator is comprised of 16 filament wires that generate electrical impulses, which cause various muscle groups to contract when stimulated. The patient thinks about moving his arm and it does so — well, sorta.
One robot has been given a simulated version of the brain cells that let animals build a mental map of their surroundings.
To whom it may concern,
Cryonics is a legitimate science-based endeavor that seeks to preserve human beings, especially the human brain, by the best technology available. Future technologies for resuscitation can be envisioned that involve molecular repair by nanomedicine, highly advanced computation, detailed control of cell growth, and tissue regeneration.
With a view toward these developments, there is a credible possibility that cryonics performed under the best conditions achievable today can preserve sufficient neurological information to permit eventual restoration of a person to full health.
Dr Michael Fossel comments on the recent Bioviva announcement of the first human gene therapy against aging.
The other day, a friend of mine, Liz Parrish, the CEO and founder of BioViva, made quite a splash when she injected herself with a viral vector containing genes for both telomerase and FST. Those in favor of what Liz did applaud her for her courage and her ability to move quickly and effectively in a landscape where red tape and regulatory concerns have – in the minds of some – impeded innovation and medical care. Those opposed to what Liz did have criticized her for moving too rapidly without sufficient concern for safety, ethics, or (from some critics) scientific rationale.
Many people have asked me to comment, both as an individual and as the founder of Telocyte. This occurs for two reasons. For one thing, I was the first person to ever advocate the use of telomerase as a clinical intervention, in discussions, in published journal articles, and in published books. My original JAMA articles (1997 and 1998), my first book on the topic (1996), and my textbook (2004) all clearly explained both the rational of and the implications for using telomerase as a therapeutic intervention to treat age-related disease. For another thing, Liz knew that our biotech firm, Telocyte, intends to do almost the same thing, but with a few crucial differences: we will only be using telomerase (hTERT) and we intend to pursue human trials that have FDA clearance, have full IRB agreement, and meet GMP (“Good Medical Production”) standards.
We cannot help but applaud Liz’s courage in using herself as a subject, a procedure with a long (and occasionally checkered) history in medical science. Using herself as the subject undercuts much of the ethical criticism that would be more pointed if she used other patients. Like many others, we also fully understand the urgent need for more effective therapeutic interventions: patients are not only suffering, but dying as we try to move ahead. In the case of Alzheimer’s disease, for example (our primary therapeutic target at Telocyte), there are NO currently effective therapies, a history of universal failure in human trials for experimental therapies, and an enormous population of patients who are currently losing their souls and their lives to this disease. A slow, measured approach to finding a cure is scarcely welcome in such a context.
Bigger isn’t always better, but in this case it might be. Research has found that a large hippocampus gives you a memory boost and may shield you from dementia.
The hippocampus is rooted deep in the brain and deals with a range of things, but it’s also a major seat of neurogenesis; making new brain cells. The seahorse shaped structure plays a leading role in translating your experiences to long term memory and it’s made up of two sides. The left helps you record language, and the right hippocampus deals with spatial memory, like an interior google map.
The seat of memory?
